| Expression pattern: |
DN |
| Associated gene: |
LATS1, SPOP, TAZ, YAP, H3K18la, LCN2 |
| Associated microRNA: |
- |
| Biological function: |
Inhibits proliferation and migration, promotes apoptosis, suppresses glycolysis and lactate production, and suppresses tumor growth and metastasis in bladder cancer. |
| Molecular mechanism: |
circXRN2 binds LATS1 at the SPOP-binding degron to prevent SPOP-mediated ubiquitination and degradation of LATS1, stabilizing LATS1 and activating Hippo signaling (TAZ/YAP cytoplasmic retention), which suppresses glycolysis/lactate and inhibits H3K18 lactylation-driven LCN2 transcription. |
| Biological pathway or process: |
Hippo/YAP (promotes); proliferation (inhibits); migration (inhibits); apoptosis (promotes); glycolysis (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RIP (RNA Immunoprecipitation); RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; FISH / smFISH; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; H&E Staining; Co-IP; Western Blot; IF (Immunofluorescence); Flow Cytometry（Non-apoptosis/cycle） |
| Clinical significance: |
- |
| Description: |
circXRN2 (hsa_circ_0001134) is down-regulated in human bladder cancer and suppresses tumor proliferation, migration, and in vivo growth/metastasis while reducing glycolysis and lactate production. Mechanistically, it binds LATS1 at the SPOP-binding degron to prevent SPOP-mediated ubiquitination/degradation, activates Hippo signaling (TAZ/YAP inhibition), and thereby reduces H3K18 lactylation and LCN2 expression. |
| Confidence score: |
0.7752 |